Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.Peter Altman, who is listed as both President and CEO and a director of BioCardia, Inc., purchased 100 shares of the company’s common stock on 08/13/2025 at a price of $1.83 per share. The filing states the transaction was executed in a single trade and is reported on a Form 4.
Following the purchase, Altman is reported to beneficially own 168,062 shares directly. The Form 4 was signed on 08/13/2025 by David McClung by power of attorney. The form indicates it was filed by one reporting person and confirms Altman’s dual role as officer and director.
BioCardia disclosure: Thomas A. Satterfield, Jr. reports beneficial ownership of 592,144 shares of BioCardia common stock, representing the maximum 9.99% ownership permitted under blocker provisions described in the filing (the EDGAR percentage field was rounded to 9.9%). The reported position comprises 465,997 directly beneficially owned shares plus an allocation of shares issuable upon exercise of warrants constrained by blocker rules to 126,147 shares for reporting purposes.
The filing shows voting and dispositive power split between sole and shared authority: 153,603 shares as sole voting/dispositive power and 438,541 shares as shared voting/dispositive power. Related entities holding securities on Mr. Satterfield's behalf include Tomsat Investment & Trading Co., Inc., A.G. Family L.P., and Caldwell Mill Opportunity Fund, LLC; a limited power of attorney is noted for 2,500 shares held by Rebecca A. Satterfield.
BioCardia, Inc. announced an exclusive development and commercialization agreement with CART‑Tech, B.V. for Heart3D™ Fusion Imaging. The Heart3D system is described as a tool to enhance two‑dimensional x‑ray images used for cardiac biotherapeutic delivery and biopsy procedures by fusing those images with annotated pre‑procedure three‑dimensional heart models created from MRI and CT scans.
The companies issued a joint press release about the agreement, and that press release is attached as Exhibit 99.1 to this report.
Peter Altman, who serves as President and CEO and is a director of BioCardia, Inc. (BCDA), reported a purchase of 400 shares of the issuer's common stock on 08/12/2025. The trades were executed in multiple fills between $1.70 and $1.83 per share, with a weighted average price of $1.751 per share. After this activity, his direct beneficial ownership is reported as 167,962 shares. The filer notes they can provide per-trade quantities and prices upon request.
Peter Altman, who serves as President and CEO and is a director of BioCardia, Inc., reported a transaction in the issuer's common stock on 08/11/2025 on Form 4. The filing shows 1,700 shares were disposed of under transaction code P.
The report lists a weighted-average sale price of $1.758 per share and states the individual trades ranged from $1.73 to $1.82. After the reported transaction, the reporting person’s direct beneficial ownership is shown as 167,562 shares. The filer notes they will provide a breakdown of the number of shares sold at each price upon request.
BioCardia reported continued clinical progress but material financing and listing risks. The company had $980,000 in cash as of June 30, 2025 and an accumulated deficit of approximately $164.9 million. Net loss was $2.049 million for the three months and $4.761 million for the six months ended June 30, 2025. Revenue was $0 for the quarter. Management states cash on hand is not sufficient to fund planned expenditures beyond October 2025 without additional financing, and the financial statements note substantial doubt about the company’s ability to continue as a going concern.
The filing highlights clinical milestones: two-year CardiAMP HF results presented with reduced all-cause death and improved composite outcomes in patients with elevated NTproBNP; plans to consult Japan’s PMDA and to seek an FDA meeting in the fourth quarter of 2025; ongoing enrollment in the CardiAMP HF II Phase 3 trial and active development of related indications and delivery systems. Nasdaq granted an extension to regain listing compliance through September 29, 2025.
BioCardia, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is being furnished rather than "filed" with the SEC, so it is not subject to the liabilities of a filed report and is not incorporated by reference into other filings unless explicitly stated.
The 8-K confirms the company’s securities trade on the Nasdaq Capital Market under the tickers BCDA (common stock) and BCDAW (warrants). No financial figures or operational details are included in the 8-K text itself; those details are contained in the furnished press release (Exhibit 99.1).
FAQ
What is the current stock price of Biocardia (BCDAW)?
